tiprankstipranks
Advertisement
Advertisement

TRVI Stock Latest News

Unusually active option classes on open April 17th
The FlyUnusually active option classes on open April 17th
13d ago
UBS
UMC
Trevi Therapeutics Prices Public Offering to Fund Haduvio
PremiumCompany Announcements
Trevi Therapeutics Prices Public Offering to Fund Haduvio
13d ago
8K
TRVI
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
PremiumThe Fly
Trevi Therapeutics 11.6M share Spot Secondary priced at $13.00
13d ago
TRVI
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
PremiumThe Fly
Closing Bell Movers: Netflix down 9% as Q2 outlook misses, Hastings leaves board
14d ago
AA
CNS
Trevi Therapeutics announces $150M common stock offering
PremiumThe Fly
Trevi Therapeutics announces $150M common stock offering
14d ago
TRVI
Trevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
PremiumRatingsTrevi Therapeutics: Positive Needham Conference Takeaways Reinforce Buy Rating and Favorable Risk‑Reward Profile
16d ago
TRVI
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
Premium
The Fly
Trevi Therapeutics price target lowered to $24 from $25 at JonesResearch
1M ago
TRVI
Trevi Therapeutics Maps Phase III Path and Runway
Premium
Company Announcements
Trevi Therapeutics Maps Phase III Path and Runway
1M ago
TRVI
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
PremiumThe Fly
Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley
1M ago
TRVI
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
PremiumThe Fly
Trevi Therapeutics reports Q4 EPS (6c), consensus (10c)
1M ago
TRVI
Trevi Therapeutics options imply 6.8% move in share price post-earnings
PremiumThe Fly
Trevi Therapeutics options imply 6.8% move in share price post-earnings
1M ago
TRVI
TRVI Earnings this Week: How Will it Perform?
PremiumPre-Earnings
TRVI Earnings this Week: How Will it Perform?
2M ago
TRVI
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
PremiumCompany AnnouncementsTrevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
2M ago
8K
TRVI
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
Premium
Ratings
De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
2M ago
TRVI
Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel
Premium
The Fly
Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel
2M ago
TRVI
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
PremiumRatings
Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi
2M ago
TRVI
Trevi Therapeutics completes End-of-Phase 2 meeting with FDA
PremiumThe Fly
Trevi Therapeutics completes End-of-Phase 2 meeting with FDA
2M ago
TRVI
Trevi announces publication of data from Phase 2b IPF chronic cough trial
PremiumThe Fly
Trevi announces publication of data from Phase 2b IPF chronic cough trial
3M ago
TRVI
Trevi Therapeutics: Favorable Risk-Reward as Haduvio Advances Toward Pivotal Chronic Cough Programs and Billion-Dollar Revenue Potential
PremiumRatings
Trevi Therapeutics: Favorable Risk-Reward as Haduvio Advances Toward Pivotal Chronic Cough Programs and Billion-Dollar Revenue Potential
4M ago
TRVI
Trevi Therapeutics price target raised to $18 from $15 at Stifel
PremiumThe FlyTrevi Therapeutics price target raised to $18 from $15 at Stifel
4M ago
TRVI
Trevi Therapeutics Appoints New Chief Financial Officer
Premium
Company Announcements
Trevi Therapeutics Appoints New Chief Financial Officer
5M ago
8K
TRVI
Trevi Therapeutics appoints David Hastings as CFO
Premium
The Fly
Trevi Therapeutics appoints David Hastings as CFO
5M ago
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >